http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2005197637-A1

Outgoing Links

Predicate Object
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61F9-0017
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0051
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4192
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-535
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61M35-00
filingDate 2004-03-02-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4a4a258380a87f8c8da232e272b7398b
publicationDate 2005-09-08-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber US-2005197637-A1
titleOfInvention Trans-scleral drug delivery method and apparatus
abstract A method of treating ocular disorders involving angiogenesis includes the steps of providing a trans-scleral drug delivery device comprising an insert stabilizer for attachment to a scleral surface and having an interlock opening and a replaceable implant having a reservoir adjacent the scleral surface and an interlock tab, wherein said insert stabilizer and said replaceable implant are removeably connectable by mating said interlock tab and said interlock opening; providing an anti-angiogenic factor; introducing said anti-angiogenic factor into said reservoir; and attaching said insert stabilizer to the scleral surface. The reservoir can be refilled by disengaging the implant from the stabilizer, inserting a new dosage of anti-angiogenic factor, and reconnecting the implant to the stabilizer or injecting a new dosage of anti-angiogenic factor into the reservoir through an injection port in the stabilizer.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2011274748-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9629826-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8614235-B2
priorityDate 2004-03-02-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6420399-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2003100558-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2005113806-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2002010176-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6413540-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2002086862-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5744492-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2002183365-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2003149051-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5602156-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2003125361-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2004198829-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2003114416-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2002188282-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6239137-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6126687-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6599910-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2003143199-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6416777-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2003013712-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2003014036-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226396440
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226471759
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID135835790
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID31307
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID111332

Total number of triples: 42.